Modification of Gemcitabine with Oxaliplatin in China for Unresectable Gallbladder Cancer: a Cost-effectiveness Analysis

Overview

Journal Front Public Health

Specialty Public Health

Date 2024 Dec 30

PMID 39735754

Authors

Zhaoyan Chen

Fangyuan Tian

Affiliations

Soon will be listed here.

Abstract

Background: The incidence of gall bladder cancer (GBC), one of the most prevalent bile duct malignancies, differs with ethnicity and geographic location. To treat unresected GBC in the Chinese setting, this study aimed to assess the financial effectiveness of a combination of modified gemcitabine and oxaliplatin.

Methods: Data from a randomized controlled study in which individuals with metastatic GBC were treated with oxaliplatin and gemcitabine demonstrated improved survival. A Markov model is built to calculate the incremental cost-benefit ratio (ICER) from the viewpoint of Chinese society on the basis of clinical symptoms and disease development. One-way certainty and probability sensitivity analyses are used to describe the uncertainty in the model.

Results: Compared with those of fluorouracil (FU) and folinic acid, the utility value of modified oxaliplatin combined with gemcitabine increased by 0.22QALY throughout the course of the 10-year simulation (FA). In a Chinese healthcare setting, the cost-effectiveness ratio (ICER) is $52765.59/QALY, with a 0% chance of cost-benefit at the WTP (willing-to-pay) level of $37697.00/QALY. The ICERs predicted by sensitivity analysis were not significantly affected by cost variations related to the management of Grade 3-4 AEs, the diagnostics used, or hospitalization expenditures.

Conclusion: In a Chinese healthcare context, modified gemcitabine coupled with oxaliplatin (mGEMOX) is not a cost-effective treatment option for unresectable GBC.

References

Lu S, Ye M, Ding L, Tan F, Fu J, Wu B . Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget. 2016; 8(6):9996-10006. PMC: 5354787. DOI: 10.18632/oncotarget.14310. View

Martins A, Nogueira T, Morais M, de Sousa-Neto S, Oton-Leite A, Valadares M . Cost-effectiveness randomized clinical trial on the effect of photobiomodulation therapy for prevention of radiotherapy-induced severe oral mucositis in a Brazilian cancer hospital setting. Support Care Cancer. 2020; 29(3):1245-1256. DOI: 10.1007/s00520-020-05607-6. View

Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D . Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004; 15(9):1339-43. DOI: 10.1093/annonc/mdh351. View

Valle J, Wasan H, Johnson P, Jones E, Dixon L, Swindell R . Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009; 101(4):621-7. PMC: 2736816. DOI: 10.1038/sj.bjc.6605211. View

Demols A, Borbath I, Van Den Eynde M, Houbiers G, Peeters M, Marechal R . Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol. 2020; 31(9):1169-1177. DOI: 10.1016/j.annonc.2020.05.018. View

Vogel D, Zhao N, Vidales C, Al-Darmaki F, Baptista M, Brenner R . Interdependent stigma of seeking mental health services: Examining a new scale across eight countries/regions. J Couns Psychol. 2024; 71(5):356-368. DOI: 10.1037/cou0000757. View

Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K . A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. J Gastrointest Cancer. 2016; 48(4):326-332. PMC: 5660135. DOI: 10.1007/s12029-016-9885-6. View

. A prospective analysis of 1518 laparoscopic cholecystectomies. N Engl J Med. 1991; 324(16):1073-8. DOI: 10.1056/NEJM199104183241601. View

Purmonen T, Martikainen J, Soini E, Kataja V, Vuorinen R, Kellokumpu-Lehtinen P . Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008; 30(2):382-92. DOI: 10.1016/j.clinthera.2008.02.013. View

10.

Miller D, Homan S . Determining transition probabilities: confusion and suggestions. Med Decis Making. 1994; 14(1):52-8. DOI: 10.1177/0272989X9401400107. View

11.

Roth J, Carlson J . Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. J Gastrointest Cancer. 2011; 43(2):215-23. DOI: 10.1007/s12029-010-9242-0. View

12.

Sharma A, Mohanti B, Raina V, Shukla N, Pal S, Dwary A . A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2009; 65(3):497-502. DOI: 10.1007/s00280-009-1055-0. View

13.

Sharma A, Dutt Dwary A, Mohanti B, Deo S, Pal S, Sreenivas V . Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010; 28(30):4581-6. DOI: 10.1200/JCO.2010.29.3605. View

14.

Xi Y, Ding Y, Cheng Y, Zhao J, Zhou M, Qin S . Evaluation of the Medical Resource Allocation: Evidence from China. Healthcare (Basel). 2023; 11(6). PMC: 10048367. DOI: 10.3390/healthcare11060829. View

15.

Doval D, Sekhon J, Gupta S, Fuloria J, Shukla V, Gupta S . A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer. 2004; 90(8):1516-20. PMC: 2409709. DOI: 10.1038/sj.bjc.6601736. View

16.

Haga Y, Miyamoto A, Wada Y, Takami Y, Takeuchi H . Value of E-PASS models for predicting postoperative morbidity and mortality in resection of perihilar cholangiocarcinoma and gallbladder carcinoma. HPB (Oxford). 2016; 18(3):271-8. PMC: 4814599. DOI: 10.1016/j.hpb.2015.09.001. View

17.

Xie B, Su Z, Liu Y, Wang M, Zhang M . Health information sources for different types of information used by Chinese patients with cancer and their family caregivers. Health Expect. 2016; 20(4):665-674. PMC: 5513017. DOI: 10.1111/hex.12498. View

18.

Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y . Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Front Pharmacol. 2022; 13:871262. PMC: 9354395. DOI: 10.3389/fphar.2022.871262. View

19.

Cho J, Nam J, Park M, Yu J, Paik Y, Lee S . A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. Yonsei Med J. 2005; 46(4):526-31. PMC: 2815838. DOI: 10.3349/ymj.2005.46.4.526. View